EDMONTON, AB - Aurora Cannabis (TSX:ACB) Inc. (NASDAQ: NASDAQ:ACB) (TSX: ACB), a Canadian medical cannabis company, has announced an expansion of its product range with new offerings from its Greybeard, San Rafael '71, and Tasty's brands. The introduction of these products is part of Aurora's commitment to providing high-quality and diverse options to Canadian consumers.
The new products, which are now available across Canada, include vape and pre-roll options that feature a variety of flavors and are designed to meet the evolving preferences of adult cannabis users. Among the new items are Banana Gas Pure Live Resin Vape by Greybeard, which promises authentic banana notes, and Country Lemon Terp Slush, a live resin extract with a bright hue and sugary texture. Additionally, Greybeard has introduced Critical Diesel Pre-Rolls, crafted from whole milled bud.
San Rafael '71 has responded to consumer demand for bulk pre-roll options with a new 20-pack of pre-rolls. Tasty's has expanded its line with several diamond-infused pre-roll flavors, including Mango, Honeydew, and Melon, all of which are enhanced with THC-A diamonds. Moreover, Tasty's has introduced a Grape 510 Vape with 1000mg of THC.
The Senior Vice President of Consumer at Aurora, Geoff Hoover, emphasized the company's focus on responding to consumer preferences with trusted and consistent products. He highlighted Aurora's use of science and superior cultivation in developing its cannabis offerings.
Aurora Cannabis operates in the medical and consumer markets across Canada, Europe, Australia, and South America, with a broad portfolio of brands for various uses, including medical and adult recreational consumption. The company's growth is driven by a focus on science and innovation, as well as high-quality cannabis products.
While the press release includes forward-looking statements about the company's expansion and innovation in its recreational product portfolio, such statements are predictions based on management's assumptions and are subject to risks and uncertainties.
This news is based on a press release statement from Aurora Cannabis Inc. and includes information about the company's latest product launches in the Canadian market.
In other recent news, Aurora Cannabis Inc. has reported substantial growth in its Q2 2025 financials. The company's net revenue rose by 29% to $81.1 million, while its adjusted EBITDA increased by a significant 210% to $10.1 million year-over-year. The company's medical cannabis revenue also saw a boost, growing by 41% to $61.3 million, with international sales up by 93%. However, it's worth noting that consumer cannabis net revenue declined to $10.4 million.
In addition to these developments, Aurora Cannabis has a robust balance sheet with $152 million in cash and no cannabis-related debt. The company anticipates continued growth in medical cannabis and positive cash flow for Q3. Despite a decrease in consumer cannabis revenue and gross margins, and increased SG&A expenses impacting profitability, the company's focus on global medical markets and innovative product offerings like CBD lozenges is expected to sustain its growth trajectory.
Analysts from various firms have noted Aurora's strong position in the global medical cannabis market, particularly in high-margin international sales. Aurora's strategic advantage in Germany with a production facility and significant growth in the self-payer market has been highlighted. The company's leadership remains optimistic about the future and its established presence in key international markets.
InvestingPro Insights
As Aurora Cannabis Inc. (NASDAQ: ACB) expands its product range, investors should consider some key financial metrics and insights from InvestingPro. The company's market capitalization stands at $229.03 million, reflecting its position in the competitive cannabis industry.
Aurora's revenue growth is noteworthy, with a 13.15% increase over the last twelve months and a more impressive 28.52% growth in the most recent quarter. This aligns with the company's strategy of expanding its product offerings to meet consumer demands, as highlighted in the article.
However, investors should be aware of some challenges. An InvestingPro Tip indicates that Aurora is "quickly burning through cash," which could be a concern given the capital-intensive nature of product development and expansion in the cannabis industry. Additionally, the company is not profitable over the last twelve months, with an operating income margin of -5.45%.
On a positive note, Aurora's liquid assets exceed its short-term obligations, suggesting a relatively stable short-term financial position. This could provide some flexibility as the company continues to innovate and introduce new products.
The stock's recent performance has been volatile, with a 25.22% decline over the past month. This volatility is reflected in another InvestingPro Tip, which notes that "stock price movements are quite volatile." This could present both risks and opportunities for investors.
For those considering an investment in Aurora Cannabis, it's worth noting that InvestingPro offers 11 additional tips for ACB, providing a more comprehensive analysis of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.